|
Oct 14
|
Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU
|
|
Aug 8
|
Orion Group Half-Year Financial Report January–June 2024
|
|
Aug 8
|
Orion Corporation’s financial reporting and Annual General Meeting in 2025
|
|
Jul 25
|
Orion publishes Half-Year Financial Report for January–June 2024 and holds a webcast on 8 August 2024
|
|
Feb 13
|
Notice to the Annual General Meeting of Orion Corporation
|
|
Feb 13
|
Orion Group Financial Statement Release January–December 2023
|
|
Jan 11
|
Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2024 Annual General Meeting
|
|
Jan 11
|
Insurance portfolio of Orion Pension Fund’s B fund transferred to an external pension insurance company – the transfer has approximately EUR 31 million positive impact on Orion’s result in 2023
|
|
Jan 8
|
Orion Corporation: Managers’ transactions – Ari Lehtoranta
|
|
Jan 8
|
Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs
|
|
Jan 5
|
Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patients with Metastatic Castration-Resistant Prostate Cancer
|
|
Dec 4
|
87 000 Orion Corporation A shares converted into B shares
|
|
Jul 19
|
Orion Corporation: Managers’ transactions – Veli-Matti Mattila
|
|
Jul 17
|
Orion Group Half-Year Financial Report 1–6/2023
|
|
Jul 17
|
Orion Corporation's financial reporting and Annual General Meeting in 2024
|